Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,336 result(s) found. Displaying page 1,791 of 2,217.
    «« First « Previous 1787  1788  1789  1790  1791  1792  1793  1794  1795  Next» Last»»
    EudraCT Number: 2021-000939-31 Sponsor Protocol Number: JDS_2021_5 Start Date*: 2021-11-02
    Sponsor Name:Hôpital Fondation A. de Rothschild / Service de recherche clinique
    Full Title: Efficacy of dornase alfa (Pulmozyme®) on arterial recanalization in post-thrombectomy angiography in patients managed for ischemic stroke by thrombolysis and eligible for thrombectomy: a monocentri...
    Medical condition: cerebral thrombectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005719-29 Sponsor Protocol Number: D-FR-52014-245 Start Date*: 2022-08-04
    Sponsor Name:Ipsen Pharma SAS
    Full Title: An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004864 10085679 Locally advanced prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) BE (Completed) ES (Ongoing) LT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002175-11 Sponsor Protocol Number: 2021-35 Start Date*: 2022-10-25
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Safety and potential effect of innovative treatment by adjuvant injection of stromal vascular Fraction from autologous adipose tissue of URethral stenosis with endoscopic urethrotomy: randomized co...
    Medical condition: URethral stenosis
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001676-29 Sponsor Protocol Number: MK3475_PROMO Start Date*: 2016-10-27
    Sponsor Name:Oslo University Hospital (OUS)
    Full Title: PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery
    Medical condition: Osteosarcoma, not eligible for curative surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-005013-47 Sponsor Protocol Number: FAAH2 Start Date*: 2017-02-28
    Sponsor Name:Linköping University
    Full Title: Effects of the FAAH inhibitor PF-04457845 on fear extinction in healthy volunteers
    Medical condition: Healthy volunteers (extinction of fear)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10016275 Fear PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011784-37 Sponsor Protocol Number: FORSS-37511 Start Date*: 2009-09-17
    Sponsor Name:Department of Orthopaedics IKE
    Full Title: Does teriparatide lower the risk for loosening of a knee prosthesis?
    Medical condition: Knee osteoarthritis. In animal studies teriparatide has shown a positive effect on fracture healing. So far, teriparatide (Forsteo ®) is only registrered for treatment of severe osteoporosis. A ce...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000826-89 Sponsor Protocol Number: 35RC21_9909_PHARM-APO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003753-13 Sponsor Protocol Number: P160909 Start Date*: 2019-03-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis
    Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001964-11 Sponsor Protocol Number: 2019/0411/HP Start Date*: 2021-12-17
    Sponsor Name:CHU de Rouen
    Full Title: Randomized double blind controlled trial comparing the safety and efficacy of apremilast versus placebo in severe forms of recurrent aphthous stomatitis
    Medical condition: Patients with severe forms of Recurrent Aphthous Stomatitis (RAS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10045372 Ulcers aphthous oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000509-58 Sponsor Protocol Number: RC31/18/0472 Start Date*: 2019-10-08
    Sponsor Name:CHU de Toulouse
    Full Title: Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhages
    Medical condition: delayed cerebral ischemia in severe subarachnoid hemorrhages
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10019587 Hemorrhage subarachnoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004490-27 Sponsor Protocol Number: 18POUM06 Start Date*: 2019-09-11
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002245-15 Sponsor Protocol Number: CCM-RNT-202102 Start Date*: 2021-05-25
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.
    Medical condition: Auto Immune Rheumatic Diseases (AIRD) and patients without rheumatic autoimmune diseases (control group).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10072736 Rheumatic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005681-29 Sponsor Protocol Number: PANDAs Start Date*: 2015-11-10
    Sponsor Name:Institut de Cancérologie de Lorraine Alexis Vautrin
    Full Title: Two arm, prospective, multicenter randomized phase II trial of neoadjuvant modified Folfirinox regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resect...
    Medical condition: Two arm, prospective, multicenter randomized phase II trial of neoadjuvant modified Folfirinox regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resect...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005208-26 Sponsor Protocol Number: P13/12 Start Date*: 2016-02-22
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVIN...
    Medical condition: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10058246 Chronic myelogenous leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022278-15 Sponsor Protocol Number: D0810C00042 Start Date*: 2010-10-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confir...
    Medical condition: Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005057-87 Sponsor Protocol Number: 337HNAS21016 Start Date*: 2022-06-15
    Sponsor Name:Inventiva S.A.
    Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin...
    Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000620-17 Sponsor Protocol Number: PPL17 Start Date*: 2019-05-08
    Sponsor Name:Dilafor AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening...
    Medical condition: Induction of labor in pregnant women with unripe cervix
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10055563 Labor induction LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-003791-13 Sponsor Protocol Number: BP42992 Start Date*: 2022-01-11
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15...
    Medical condition: Dup15q Syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083952 Dup15q syndrome LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1787  1788  1789  1790  1791  1792  1793  1794  1795  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:14:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA